Library / Peptides / Recovery & Healing / BPC-157
Emerging evidence · Grade B

BPC-157

BPC-157 (Body Protection Compound-157)
Evidence
Emerging
Route
Subcutaneous injection
Frequency
1-2x daily
Category
Recovery & Healing
TL;DR
BPC-157 is a peptide derived from a stomach protein that shows dramatic healing effects in animal studies — accelerating recovery of tendons, muscles, gut, and nerves. The preclinical evidence is extensive and consistent, which is why it has gained a large following in athletic and recovery communities. However, human clinical trials have not been completed, so we do not yet know if these effects translate to people, what the right dose is, or what the long-term risks are.
Part 01 · How it works

Mechanism.

BPC-157 is a synthetic pentadecapeptide (15 amino acids) derived from a partial sequence of body protection compound found in human gastric juice. It has demonstrated remarkable tissue-healing, inflammation-modulating, and gastroprotective properties across hundreds of animal studies covering tendon, muscle, bone, gut, nerve, and corneal injuries. Despite extensive preclinical data, no completed Phase II or III human clinical trials exist, creating a significant evidence gap between animal and human data.

If tissue healing is like rebuilding a city after a disaster, BPC-157 acts like an emergency dispatcher that simultaneously calls in the construction crews (fibroblasts), turns on the water supply (angiogenesis), calms the fires (inflammation), and clears the roads so supply trucks can get through — all at the same time.

Mechanism · technical
BPC-157 promotes angiogenesis through upregulation of VEGF and VEGFR2, accelerating formation of new blood vessels into injured tissue. It activates FAK (focal adhesion kinase) and paxillin signaling pathways in fibroblasts and myocytes, promoting cell migration and tissue repair. It modulates nitric oxide (NO) synthesis, supports growth hormone receptor expression in injured tissue, and exerts gastroprotective effects by maintaining mucosal integrity and cytoprotective prostaglandin pathways. Inflammation-modulating effects involve NF-κB suppression.
Part 02 · Dosing & administration

How it's taken.

Values below describe how BPC-157 has been administered in published trials and labeling. Provided for educational purposes only — this is not medical advice and not instructions for self-administration. Consult your healthcare provider before making any health decision.

Standard dose
250-500 mcg
Subcutaneous injection · 1-2x daily
Duration
4-8 weeks typical cycle

Often dosed BID near injury site. No established clinical protocol — based on available research literature — no FDA-approved protocol exists. Also available in oral capsule form for GI applications.

Need help with reconstitution?

Use the free peptide calculator for dilution, unit conversion, and injection volume.

Open calculator
Part 03 · Safety

Side effects, rare serious events, who shouldn't.

Reported side effects
No significant adverse effects have been identified in animal studies even at very high doses. Human case series and anecdotal reports describe good tolerability. Theoretical concerns include pro-angiogenic effects potentially stimulating tumor vasculature. No long-term human safety data exists.
Absolute · do not use
×
Active cancer or history of cancer (may promote angiogenesis)
×
Pregnancy or breastfeeding
×
Children under 18
×
Known hypersensitivity to BPC-157 or any component
Interactions
Anticoagulants (warfarin, heparin)
BPC-157 may affect platelet aggregation and wound healing pathways, potentially altering bleeding risk
Moderate
NSAIDs (ibuprofen, naproxen)
May have additive inflammation-modulating effects; monitor GI symptoms
Minor
Immunosuppressants
BPC-157 modulates immune function which may interfere with immunosuppressive therapy
Moderate
Dopaminergic medications (L-DOPA, dopamine agonists)
BPC-157 influences dopamine system; may potentiate or interfere with dopaminergic drugs
Moderate
Labs to monitor
CBC with Differential
Baseline and monthly
Monitor for blood count changes
CMP (Comprehensive Metabolic Panel)
Baseline and every 3 months
Liver and kidney function
CRP / ESR
Baseline and monthly
Track inflammatory markers
Coagulation Panel (PT/INR)
Baseline
BPC-157 may affect angiogenesis and blood vessel formation
Part 04 · Evidence

How strong is the evidence?

Scores derived from rating, indexed studies, regulatory status, and catalogued safety data for this peptide. Curated per-peptide scoring replaces this when available.

75
Grade B
Grade B. Signal is real but maturing. Treat results as directional until larger or independent replications land.
Clinical efficacy
Emerging signal across multiple indexed studies; effect sizes still firming up.
68
Study quality
4 indexed studies in our dataset. Designs vary — see Research log for per-study grades.
87
Regulatory clarity
FDA-approved for at least one indication.
90
Safety profile
Based on 4 documented contraindications, 4 interactions, 4 lab checkpoints.
84
Long-term data
Long-horizon data not yet available outside research settings.
48
Part 05 · Research log

Every study we cite.

Each study with its published finding and a plain-language note on limitations or funding.

01
2010
0
BPC-157 accelerates healing of transected rat Achilles tendon
BPC-157 systemically and locally administered significantly accelerated tendon healing, restored mechanical strength, and improved histological appearance versus saline controls in a complete Achilles tendon transection model.
Rodent model. Doses used may not translate directly to human dosing. No human equivalent study exists.
PMID 20175021 ↗
02
2012
0
Gastroprotective effects of BPC-157 in NSAID-induced gut injury
BPC-157 prevented and reversed aspirin- and indomethacin-induced gastric and intestinal lesions in rats, likely through maintenance of mucosal blood flow and cytoprotective prostaglandin pathways.
Animal study. Mechanism plausible for human IBD/NSAID ulcer but requires RCT validation in humans.
PMID 22369999 ↗
03
2015
0
BPC-157 in peripheral nerve injury: regeneration and functional recovery
BPC-157 treatment significantly improved nerve regeneration, myelination, and functional recovery after sciatic nerve crush injury in rats compared to controls.
Animal model only. Clinical implications for human nerve injury are speculative.
PMID 26055715 ↗
04
2022
0
Systematic review of BPC-157: evidence base and translational challenges
A systematic review identified over 100 preclinical studies showing consistent healing effects across tissue types but concluded that the complete absence of human RCT data prevents clinical recommendations.
Review highlights the fundamental limitation: the entire evidence base is preclinical. The absence of phase II/III trials after decades of preclinical work is notable.
PMID 35311129 ↗
Part 06 · Cost & access

Where you can get it.

Regulatory status
Not FDA-approved. Not approved in any country as a pharmaceutical. Listed by WADA as a banned substance in sport. Available as a research peptide in the US. FDA has taken action against some suppliers. No IND exists for widespread BPC-157 trials. Australian TGA has banned its sale as a supplement.
The Peptide Column takes no affiliate commission from any source.
Part 07 · Your appointment

Questions to bring.

01
Are there any active clinical trials of BPC-157 I might qualify for given my injury or gut condition?
02
Is there a risk that BPC-157's pro-angiogenic effects could promote growth of existing or undetected tumors?
03
What form of BPC-157 (injectable vs. oral) is most appropriate for my specific use case?
04
How does BPC-157 interact with NSAIDs, corticosteroids, or other medications I take?